Review article: The stages of gastrointestinal carcinogenesis - Application of rodent models to human disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 14, Issue 1, 2000, Pages 153-160

  Pitot, H C ^a   Hikita, H ^a   Dragan, Y ^a   Sargent, L ^a   Haas, M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CANCER MODEL; CARCINOGENESIS; COLON CARCINOGENESIS; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; HUMAN; NONHUMAN; ONCOGENE C MYC; PRECANCER; PRIORITY JOURNAL; RAT; RODENT; TUMOR SUPPRESSOR GENE;

EID: 0034033334     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.014s1153.x     Document Type: Conference Paper

References (46)

1. Pitot HC. Multistage carcinogenesis. In: Bertino JR, eds. Encyclopedia of Cancer, Vol II. San Diego: Academic Press, 1997.
2. Pitot HC III, Dragan YP. Chemical carcinogenesis. In: Klaasen CD, eds. Casarett and Doull's Toxicology - the Basic Science of Poisons. New York: McGraw-Hill, 1996: 201-67.
3. Pitot HC, Dragan YP, Teeguarden J, Hsia S, Campbell H. Quantitation of multistage carcinogenesis in rat liver. Toxicol Pathol 1996; 24: 119-28.
4. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmac Ther 1992; 54: 63-128.
5. Solt DB, Calderon-Solt L, Odajima T. Rapid induction of carcinomas and y-glutamyl transpeptidase-rich clones in N-methyl-N-benzylnitrosamine-treated hamster buccal pouch. J Natl Cancer Inst 1985; 74: 437-45.
6. Moore MA, Nakagawa K, Satoh K, Ishikawa T, Sato K. Single GST-P positive liver cells - putative initiated hepatocytes. Carcinogenesis 1987; 8: 483-6.
7. Winokur TS, Lieberman MW. Immunofluorescent analysis of γ-glutamyl transpeptidase and glutathione-S-transferase-P during the initial phase of experimental hepatocarcinogenesis. Carcinogenesis 1990; 11: 365-9.
8. Nakano H, Hatayama I, Satoh K, Suzuki S, Sato K, Tsuchida S. c-Jun expression in single cells and preneoplastic foci induced by diethylnitrosamine in B6C3F1 mice: comparison with the expression of pi-class glutathione S-transferase. Carcinogenesis 1994; 15: 1853-7.
9. Buchmann A, Mahr J, Bauer-Hofmann R, Schwarz M. Mutations at codon 61 of the Ha-ras proto-oncogene in precancerous liver lesions of the B6C3F1 mouse. Mol Carcinog 1989; 2: 121-5.
10. Pretlow TP, O'Riordan MA, Kolman MF, Jurcisek JA. Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity. Am J Pathol 1990; 136: 13-6.
11. Tachino N, Hayashi R, Liew C, Bailey G, Dashwood R. Evidence for ras gene mutation in 2-amino-3-methylimidazo[4,5-f]quinoline-induced colonie aberrant crypts in the rat. Mol Carcinog 1995; 12: 187-92.
12. Shpitz B, Bomstein Y, Mekori Y. et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998; 29: 469-75.
13. Smith AJ, Stern HS, Penner M, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994; 54: 5527-30.
14. Pitot H, Dragan Y, et al. Characterization of the stages in gastroenterological carcinogenesis. In: Tahara E, Sugimachi K, Oohara T, eds. Recent Advances in Gastroenterological Carcinogenesis I. Bologna, Italy: Monduzzi Editore S.p.A., 1996: 11-9.
15. Enzmann H, Ohlhauser D, Enzmann H, et al. Unusual histochemical pattern in preneoplastic hepatic foci characterized by hyperactivity of several enzymes. Virchows Arch B Cell Pathol 1989; 57: 99-108.
16. Dragan Y, Teeguarden J, Campbell H, Hsia S, Pilot H. The quantitation of altered hepatic foci during multistage hepatocarcinogenesis in the rat: transforming growth factor a expression as a marker for the stage of progression. Cancer Lett 1995; 93: 73-83.
17. Tudek B, Bird RP, Bruce WR. Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res 1989; 49: 1236-40.
18. Cayama E, Tsuda H, Sarma DSR, Farber E. Initiation of chemical carcinogenesis requires cell proliferation. Nature 1978; 275: 60-2.
19. Ishikawa T, Takayama S, Kitagawa T. Correlation between time of partial hepatectomy after a single treatment with diethylnitrosamine and induction of adenosinetriphosphatase-deficient islands in rat liver. Cancer Res 1980; 40: 4261-4.
20. Pitot HC. Stages in neoplastic development. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention, 2nd edn. New York: Oxford University Press, 1996: 65-79.
21. Hoff G, Foerster A, Vatn MH, Sauar J, Larsen S. Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after delection. Scand J Gastroenterol 1986; 21: 853-62.
22. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-9.
23. Nandurkar S, Talley NJ. Surveillance in Barrett's oesophagus: a need for reassessment? J Gastroenterol Hepatol 1998; 13: 990-6.
24. Williams GM, Watanabe K. Quantitative kinetics of development of N-2 fluorenylacetamide-induced, altered (hyperplastic) hepatocellular foci resistant to iron accumulation and of their reversion or persistence following removal of carcinogen. J Natl Cancer Inst 1978: 1: 113-21.
25. Hendrich S, Glauert HP, Pitot HC. The phenotypic stability of altered hepatic foci: effects of withdrawal and subsequent readministration of phenobarbital. Carcinogenesis 1986; 7: 2041-5.
26. Greaves P, Irisarri E, Monro AM. Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility. J Natl Cancer Inst 1986; 76: 475-84.
27. Enomoto K, Farber E. Kinetics of phenotypic maturation of remodeling of hyperplastic nodules during liver carcinogenesis. Cancer Res 1982; 42: 2330-5.
28. Buhler H, Pirovino M, Akovbiantz A, et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982; 82: 775-82.
29. Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977; 86: 1802.
30. O'Connor TP, Roebuck BD, Campbell TC. Dietary intervention during the postdosing phase of L-azaserine-induced preneoplastic lesions. J Natl Cancer Inst 1985; 75: 955-7.
31. Nera EA, Iverson F, Lok E, Armstrong CL, Karpinski K, Clayson DB. Carcinogenesis reversibility study of the effects of butylated hydroxyamsole on the forestomach and urinary bladder in male Fischer 344 rats. Toxicology 1988; 53: 251-68.
32. Masui T, Asamoto M, Hirose M, Fukushima S, Ito N. Regression of simple hyperplasia and papillomas and persistence of basal cell hyperplasia in the forestomach of F344 rats treated with butylated hydroxyanisole. Cancer Res 1987; 47: 5171-4.
33. Rugge M, Farinati F, Di Mario F, Baffa R, Valiante F, Cardin F. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol 1991; 22: 1002-8.
34. Benner SE, Winn RJ, Lippman SM, et al. Regression of oral leukoplakia with alpha-tocopherol: a Community Clinical Oncology Program chemoprevention study. J Natl Cancer Inst 1993; 85: 44-7.
35. Hikita H, Nuwaysir EF, Vaughan J. et al. The effect of short-term fasting, phenobarbital and refeeding on apoptotic loss, cell replication and gene expression in rat liver during the promotion stage. Carcinogenesis 1998; 19: 1417-25.
36. Pitot HC. Multistage Carcinogenesis - genetic and epigcnetic mechanisms in relation to cancer prevention. Cancer Detect Preven 1993; 17: 567-73.
37. Pitot HC. The molecular biology of Carcinogenesis. Cancer 1993; 72: 962-70.
38. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
39. Sainati L, Leszl A, Stella M, et al. Cytogenetic analysis of hepatoblastoma: hypothesis of cytogenetic evolution in such tumors and results of a multicentric study. Cancer Genet Cytogenct 1998; 104: 39-44.
40. Sargent L, Dragan Y, Xu Y-H, Sattler G, Wiley J, Pitot HC. Karyotypic changes in a multistage model of chemical hepatocarcinogenesis in the rat. Cancer Res. 1996; 56: 2985-91.
41. Sargent LM, Dragan YP, Sattler G, Xu Y-H, Wiley J, Pitot HC. Specific chromosomal changes in albumin simian virus 40 T antigen transgenic rat liver neoplasms. Cancer Res 1997; 57: 3451-6.
42. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumour-suppressor activity of H19 RNA. Nature 1993; 365: 764-7.
43. Yuan L, Qian N, Tycko B. An extended region of biallelic gene expression and rodent human synteny downstream of the imprinted H19 gene on chromosome 11p15.5. Hum Mol Genet 1996; 5: 1931-7.
44. Thorvaldsen JL, Duran KL, Bartolomei MS. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev 1998; 12: 3693-702.
45. Cui H, Hedborg F, He L, et al. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis. Cancer Res 1997; 57: 4469-73.
46. Ooasa T, Karasaki H, Kanda H, Nomura K, Kitagawa T, Ugawa K. Loss of imprinting of the insulin-like growth factor 11 gene in mouse hepatocellular carcinoma cell lines. Mol Carcinog 1998; 23: 248-53.